Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Intraday data delayed at least 15 minutes or per exchange requirements. quotes delayed at least 15 minutes, all others at least 20 minutes. Nasdaq During the same period in the previous year, the business earned ($2.00) earnings per share. While ALNY stock may see higher levels, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. In the past three months, Alnylam Pharmaceuticals insiders have sold more of their company's stock than they have bought. After moving 1% or more over a ten-day period, the stock rose in the next ten days on 54% of the occasions. Why Baidu Stock Looks Undervalued At $123, Law Enforcement Can Overcome The Illicit Cannabis Market, Generative AI Could Sustain Arista Networks 31% Annual Stock Growth, Alnylam Pharmaceuticals Stock Return: AI Predicts ALNY Average and Excess Return After a Fall or Rise, average return for the S&P 500 after a fall or rise, Alnylam Pharmaceuticals stock dropped 15% on 10/28/2021, compared to broader market (S&P500) rise of 1.0%, A change of -15% or more over 1 trading day is an extremely rare event, which has occurred 3 times out of 2516 in the last 10 years, Alnylam Pharmaceuticals stock declined 8.6% the last twenty-one trading days (one month), compared to broader market (S&P500) rise of 5.5%, A change of -8.6% or more over twenty-one trading days is a 20% likelihood event, which has occurred 498 times out of 2516 in the last 10 years, Of these 498 instances, the stock has seen a positive movement over the next twenty-one trading days on 317 occasions, This points to a 64% probability for the stock rising over the next twenty-one trading days. The stock price of Alnylam Pharmaceuticals, a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, has seen a 4.1% drop over the last five trading days, after another pharmaceutical company - Intellia Therapeutics - announced positive findings from clinical trials for NTLA-2001, an experimental treatment for transthyretin amyloidosis using CRISPR gene editing. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. According to Alnylam Pharmaceuticals, the study also met the first secondary endpoint of change from baseline in quality of life compared to a placebo. View institutional ownership trends. ALNY earnings call for the period ending March 31, 2021. $141.97 would only be a pit stop, though. See what's happening in the market right now with MarketBeat's real-time news feed. Furthermore, the company announced a change in top leadership with its current CEO - John Maraganore - stepping down at the end of 2021, and the current company president and chief operating officer - Yvonne Greenstreet - to be the next CEO. Its products include ONPATTRO, GIVLAARI, and OXLUMO. Get 30 Days of MarketBeat All Access Free, By creating a free account, you agree to our, Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences. How many employees does Alnylam Pharmaceuticals have? That includes why shares of Kiora Pharmaceuticals(NASDAQ:KPRX), Better Choice (NYSEMKT:BTTR), and Yunji (NASDAQ:YJ) stock are on the move today. Earnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($6.46) to ($3.17) per share. Alnylam Pharmaceuticals drug, patisiran (brand name ONPATTRO), is designed to treat some symptoms of hereditary transthyretin-mediated amyloidosis. Interestingly, though, if a stock has gained over the last few days, you would do better to avoid short-term bets for most stocks - although ALNY stock appears to be an exception to this general observation. The stock price of Alnylam Pharmaceuticals, a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, plunged over 15% in yesterdays trading session, following its Q3 results, which were much lower than the Wall Street estimates. ALNY stock holders are cheering Alnylam's success in advancing a highly targeted treatment. Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars, CrowdStrike: Another Tech Stock to Buy on the Dip, Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets. Only 1.40% of the stock of Alnylam Pharmaceuticals is held by insiders. To see all exchange delays and terms of use please see Barchart's disclaimer. Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) price-to-sales (or "P/S") ratio of 20.1x might make it look like a strong sell right now compared to the Biotechs industry in the United States, where . The company also announced a CEO transition at the end of the year. 5 Artificial Intelligence Stocks to Buy Before They Skyrocket, This No-Name Street in San Francisco Is the Birthplace of the Next Big Megatrend, Louis Navellier and the InvestorPlace Research Staff, Miracle Psychedelics Could Save Lives and Mint Millions, Dear BBBYQ Stock Fans, Mark Your Calendars for June 14, 3 Stocks to Buy That Could Be the Next Nvidia, Dear SOFI Stock Fans, Mark Your Calendars for June 14. Its an exciting day, clearly, for Alnylam Pharmaceuticals and the companys long-term shareholders. Alnylam's drug reportedly met its. Weak revenue is a trend for SentinelOne today with its Q1 earnings including $133.4 million. ALNY earnings call for the period ending September 30, 2021. Why Is Better Choice (BTTR) Stock Up 27% Today? Can Presto Automation Bring AI to the Drive-Thru? Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Alnylam Pharmaceuticals, Inc.'s score of 78 means that it ranks higher than 78% of stocks in the sector. Recent times have been advantageous for Alnylam Pharmaceuticals as its revenues have been rising faster than most other companies. Their ALNY share price forecasts range from $143.00 to $415.00. All quotes are in local exchange time. You're all set to receive the Morning Update newsletter. Sharp on June 14, 2002 and is headquartered in Cambridge, MA. Salesforce: Time to Snap it Up as the Market Buys the Dip? What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings? Opinions expressed by Forbes Contributors are their own. After moving 3% or more over a five-day period, the stock rose in the next five days on 53% of the occasions. ALNY earnings call for the period ending June 30, 2021. Intraday Data provided by FACTSET and subject to terms of use. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. BRAZIL - 2020/10/07: In this photo illustration the Alnylam Pharmaceuticals logo seen displayed on a [+] smartphone. Alnylam Pharmaceuticals (ALNY) Stock Forecast, Price & News $185.01 -1.45 (-0.78%) (As of 05/31/2023 ET) Compare Today's Range $183.88 $190.45 50-Day Range $185.01 $212.05 52-Week Range $120.43 $242.97 Volume 893,594 shs Average Volume 775,155 shs Market Capitalization $23.04 billion P/E Ratio N/A Dividend Yield N/A Price Target $247.20 You can test the chance of recovery over different time intervals of a quarter, month, or even just one day! For the best MarketWatch.com experience, please update to a modern browser. Meanwhile, Alnylam Pharmaceuticals Chief Medical Officer Pushkal Garg took a moment to tout the clinical implications of his companys clinical-trial outcomes: These patients have limited treatment options, and disease progression is common. May 23, 2023|markets.businessinsider.com, May 22, 2023|markets.businessinsider.com. The company has a market cap of $23.04 billion, a price-to-earnings ratio of -21.29 and a beta of 0.48. The biopharmaceutical company earned $319.29 million during the quarter, compared to analyst estimates of $312.53 million. Earnings per share (EPS) also surpassed analyst estimates by 19%. Identify stocks that meet your criteria using seven unique stock screeners. 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Thanks to a little-known IRS loophole Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the Amazon secret royalty program Delta Air Lines Stock Poised For Strong Gains? Alnylam Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $251.27, which is a 34.8% upside from current levels. See our analysis on Alnylam Stock Return for more details. Learn More. Up to 15 opportunities a day. Alnylam Pharmaceuticals, Inc. (ALNY) Latest Stock News & Headlines - Yahoo Finance ALNY - Alnylam Pharmaceuticals, Inc. NasdaqGS - NasdaqGS Real Time Price. For long-term investors, one disappointing quarter and a CEO transition should not make you immediately sell your stake in Alnylam Pharmaceuticals. In . Shares of ALNY stock opened at $185.01 on Thursday. These three biotech companies could be headed for a buyout soon. The company missed analysts' Q3 revenue expectations and announced the departure of its CEO. In the premarket this morning, Alynlam Pharmaceuticals released its results for the third quarter. Identify stocks that meet your criteria using seven unique stock screeners. Now, is ALNY stock poised to see lower levels or is a rise imminent? In addition, its overall score of 87 ranks it higher than 87% of all stocks. ALNY stock has since rallied 19% to levels of over $200 currently. Subscriber Agreement & Terms of Use | View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. This result for patisiran was measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ). American Consumer News, LLC dba MarketBeat 2010-2023. The single greatest medical breakthrough of all time? Why Are Telecom Stocks T, VZ, TMUS Down Today? Upgrade to MarketBeat All Access to add more stocks to your watchlist. Laser breakthrough could send stock soaring 2,467% (Ad), "Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad), Trading Channel Breakout in Lululemon Brought by Earnings, Constellation Brands Taps into Growth: Analysts Bullish on Stock, High-Quality, High-Yield Hormel Looks Tasty at These Levels. quotes delayed at least 15 minutes, all others at least 20 minutes. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. We track news headlines from hundreds of news outlets and tag them by company. Pay Attention to This Semiconductor Stock Instead, Investing $1,000 in This Nearly 10%-Yielding Dividend Stock Could Be a Wise Move in June, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. In the third-quarter results, management highlighted four different drugs that are in the research and development phase for Alnylam to go with the four it already has on the market. Get Ready for Health-Care Stocks to Go Wild. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Get daily stock ideas from top-performing Wall Street analysts. Renewed Analyst Sentiment for CBRE Group Stock: Buy the Dip? Theres a whole lot of scientific terminology in Alnylam Pharmaceuticals press release. Onpattro sales stood at $306 million in 2020, while its peak is estimated to be over $2 billion. Looking ahead, revenue is forecast to grow 31% p.a. The P/E ratio of Alnylam Pharmaceuticals is -22.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. Calculation of Event Probability and Chance of Rise using last ten years data, Predict average return on Alnylam Pharmaceuticals Stock Return: AI Predicts ALNY Average and Excess Return After a Fall or Rise, Alnylam Pharmaceuticals Stock Return (Recent) Comparison With Peers And S&P500, [Updated: June 30, 2021] ALNY Stock Decline. Vol.) In a report released today, Luca Issi from RBC Capital reiterated a Buy rating on Alnylam Pharma, with a price target of $275.00. The company's average rating score is 2.71, and is based on 15 buy ratings, 6 hold ratings, and no sell ratings. Amazon Loophole could hand you $28,544 in royalty payouts. Despite a threat from Intellia on the horizon, Alnylam's still in a position to deliver big gains for patient investors. Will Summer Be A Quiet Season For Markets? The company's earnings fell short of expectations and its CEO is leaving. Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars, CrowdStrike: Another Tech Stock to Buy on the Dip, Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets. How can I contact Alnylam Pharmaceuticals? If you're unsure about the strength of Alnylam Pharmaceuticals' business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed. Why Is Alnylam (ALNY) Stock Up 50% Today? Heres a high-quality portfolio thats beaten the market consistently since 2016. Theres more stock market news traders will want to know about below! Now that ALNY stock has fallen 4% in just five days, will it resume its downward trajectory over the coming weeks, or is a rise in the stock imminent? Unless these conditions improve markedly, it's very challenging to accept these prices as being reasonable. Specifically, they have bought $0.00 in company stock and sold $7,131,842.00 in company stock. See how to collect the next payout before the strict cutoff deadline. In-depth profiles and analysis for 20,000 public companies. Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. 5 Artificial Intelligence Stocks to Buy Before They Skyrocket. So, if it follows its historical pattern, it is likely that ALNY stock will see higher levels. Invest with Trefis Market-Beating Portfolios, This is a BETA experience. Alnylam Pharmaceuticals (ALNY) dipped Monday amid reports that Novartis (NVS) is closing a significant . Feb. 15, 2022 4:25 AM ET Alnylam Pharmaceuticals, Inc. (ALNY) 5 Comments Stephen Simpson 18.89K Follower s Follow Summary Alnylam has multiple clinical read-outs coming over the next 12. Retrospectively, the last year delivered an exceptional 30% gain to the company's top line. Something went wrong while loading Watchlist. What if youre looking for a more balanced portfolio instead? Click Here to get the full Stock Report for Alnylam Pharmaceuticals, Inc. stock. Going by historical performance, there is a slightly higher chance of more gains in ALNY stock over the next month. Is This Unknown Growth Stock a Buy After Its Blast Off? Vir Will Test Its Covid-19 Antibody With Eli Lillys, Sending Shares Up Again. Will this hurt aspiring homeowners? A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. In a report released today, Robert Wasserman from Benchmark Co. reiterated a Buy rating on Emergent Biosolutions, with a price target of $22.00. In a report issued on May 16, BMO Capital also maintained a Buy rating on the stock with a $250.00 price target. One-Stock Millionaire IGNORES 99.9% of the Market. Nasdaq Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Cookie Notice (). That failed to reach the $136.61 million in revenue that Wall Street was expecting. As such, we look at the stock performance over the last month or so to have a better sense of the pattern after a fall. Keen to find out how analysts think Alnylam Pharmaceuticals' future stacks up against the industry? Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. American Consumer News, LLC dba MarketBeat 2010-2023. ALNY has an Overall Score of 87. Please log in to your account or sign up in order to add this asset to your watchlist. Dave Bernhardt, chief financial officer of SentinelOne, said the following in the earnings report: Even in a tough quarter, we achieved our seventh consecutive quarter of over 25 percentage points year-over-year improvement in operating margins. Were committed to selectively investing in key growth areas, managing our cost structure, and achieving our profitability targets.. Get short term trading ideas from the MarketBeat Idea Engine. Invest better with The Motley Fool. More specifically, Alnylam tested patisiran in transthyretin-mediated amyloidosispatients with cardiomyopathy. Alnylam Pharmaceuticals has received a consensus rating of Buy. How much money does Alnylam Pharmaceuticals make? Investing in stocks, bonds, option and other financial instruments involve risks and may not be suitable for everyone. (Photo Illustration by Rafael Henrique/SOPA Images/LightRocket via Getty Images), [Updated: November 01, 2021] ALNY Stock Decline. Alnylam's Strategy Is Getting Bigger. Mortgage rates rise to highest level in six months. Article printed from InvestorPlace Media, https://investorplace.com/2023/06/why-is-sentinelone-s-stock-down-37-today/. View which stocks are hot on social media with MarketBeat's trending stocks report. During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers money 26 TIMES Copyright News & Analysis Financial Health Valuation Podcast Episodes Earnings Transcripts Related Stocks Key Data Points Current Price $190.97 Daily Change (-7.4%) -$15.23 Day's Range $189.20 - $202.70. Demand is likely to weaken, Freddie Mac says. We've written a bit before about zero-day-to-expiry (0DTE) options, a newish set of financial instruments that have . A couple of months back we discussed that the stock price of Alnylam Pharmaceuticals, a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, may see a rebound after seeing a small decline due to positive data for Intellias NTLA-2001, an experimental treatment for transthyretin amyloidosis using CRISPR gene editing. 3 Can't-Miss Biotech Events Coming Up in 2022, Why Alnylam Pharmaceuticals Stock Is Tanking This Week, Why Alnylam Pharmaceuticals Is Crashing Today, 5 Reasons Alnylam's Still a Top Biotech Stock to Buy Now, Alnylam Pharmaceuticals, inc (ALNY) Q3 2021 Earnings Call Transcript, Motley Fool Transcribers|Oct 29, 2021, Alnylam Pharmaceuticals, inc (ALNY) Q2 2021 Earnings Call Transcript, Alnylam Pharmaceuticals Inc (ALNY) Q1 2021 Earnings Call Transcript, Motley Fool Transcribers|Apr 29, 2021, Alnylam Pharmaceuticals Inc (ALNY) Q4 2020 Earnings Call Transcript, Motley Fool Transcribers|Feb 11, 2021, Copyright, Trademark and Patent Information. Who are Alnylam Pharmaceuticals' major shareholders? We'll send you a email rounding up the latest S&P 500 news every morning. In fact, it will be prudent for long-term investors to use any dips in ALNY stock to buy for better returns. A rating of 78 puts Alnylam Pharmaceuticals, Inc. (ALNY) near the top of the Healthcare sector according to InvestorsObserver. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. After moving 11% or more over a twenty-one-day period, the stock rose in the next twenty-one days on 54% of the occasions. Learn about the media coverage comparison. The Fool has written over 200 articles on Alnylam Pharmaceuticals. Revenue came in at $187.6 million in the period, missing analyst estimates by a wide margin. ALNY earnings call for the period ending December 31, 2020. More Articles Price Area Volume: Previous Close - Market Cap 22.80B PE Ratio -22.07 EPS -8.69 Volume (Avg. Compare Top Brokerages Here. According to TipRanks.com, Gordon is ranked #3657 out of 8379 analysts. Dell Tops Q1 Estimates but Fails to Deliver on Guidance, 'Unknown laser company making HUGE profit from Russia-Ukraine War', RBC Capital Reiterates Alnylam Pharmaceuticals (ALNY) Outperform Recommendation, Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Bristol Myers (BMY), Head to Head Contrast: Alnylam Pharmaceuticals (NASDAQ:ALNY) & Syros Pharmaceuticals (NASDAQ:SYRS), U.S. FDA approves Lexicon Pharma's drug for heart failure, Pfizer, Moderna hit with new Alnylam patent lawsuits over COVID-19 vaccines, H.C. Wainwright Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR), Analyst Says Alnylam's New Patisiran Data Shows Disease Slowing With Early Intervention, But Survival Benefit Remains Of Interest, Laser breakthrough could send stock soaring 2,467%, Alnylam (ALNY) Reports Positive Results From APOLLO-B Study, Alnylam Pharmaceuticals (NASDAQ:ALNY) Now Covered by Analysts at StockNews.com, Analysts Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Price Target at $247.20, Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading Down 5.3%, Analysts Are Bullish on These Healthcare Stocks: Alnylam Pharma (ALNY), Disc Medicine (IRON), Familial Amyloid Polyneuropathy Therapeutic Market Insights [2023]| Explained Current Growth for Upcoming Period 2031, Systemic Amyloidosis Market Forecast and Analysis: 2023-2031, Citigroup Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM), H.C. Wainwright Remains a Buy on Alnylam Pharma (ALNY), Alnylam Pharmaceuticals (NASDAQ:ALNY) Lifted to Buy at StockNews.com, Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to Outperform at BMO Capital Markets, Analysts Opinions Are Mixed on These Healthcare Stocks: Alnylam Pharma (ALNY), Qiagen (QGEN) and Teleflex (TFX), Alnylam (ALNY) Q1 Earnings Beat, Product Sales Drive Revenues, Alnylam Pharma (ALNY) Receives a Buy from BMO Capital, Needham Reaffirms Their Buy Rating on Alnylam Pharma (ALNY), Needham Reiterates Alnylam Pharmaceuticals (ALNY) Buy Recommendation, BMO Capital Upgrades Alnylam Pharmaceuticals (ALNY), Berenberg Bank Keeps Their Hold Rating on Alnylam Pharma (ALNY), view top-rated stocks among Wall Street analysts, ETFMG Treatments Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM), American CenturyFocused Dynamic Growth ETF (FDG), First Trust NYSE Arca Biotechnology Index Fund (FBT), Principal Healthcare Innovators ETF (BTEC), 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. Why Are Telecom Stocks T, VZ, TMUS Down Today? The biopharmaceutical company reported ($1.40) EPS for the quarter, beating the consensus estimate of ($1.97) by $0.57. 3 Can't-Miss Biotech Events Coming Up in 2022, A Bull Market Is Coming: Here's Warren Buffett's Life-Changing Investing Advice, 2 Super Stocks Down 24% and 70% You'll Regret Not Buying on the Dip, Missed Nvidia Stock? Transthyretin-mediated amyloidosisis a rare and debilitating disease that involves the nerves, heart, and gastrointestinal (GI) tract. According to analysts' consensus price target of $247.20, Alnylam Pharmaceuticals has a forecasted upside of 27.6% from its current price of $193.67. You need to take note of risks, for example - Alnylam Pharmaceuticals has 3 warning signs (and 1 which makes us a bit uncomfortable) we think you should know about. Real-time analyst ratings, insider transactions, earnings data, and more. The companys shares closed last Wednesday at $8.29, close to its 52-week low of $7.74. Different types of transthyretin-mediated amyloidosis affect tens of thousands, or even hundreds of thousands of people worldwide. Blackstones $3.45 Billion Deal For Lab Space Shows Boom in Life Sciences, A Top Contender in the Race for a NASH Drug Drops Out, These 23 companies are working on coronavirus treatments or vaccines heres where things stand, Blackstones Byron Wien Weighs In on Employment, China, and the Health-Care System, Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Bristol Myers (BMY), Analysts Opinions Are Mixed on These Healthcare Stocks: Alnylam Pharma (ALNY), Galapagos (GLPG) and Emergent Biosolutions (EBS), What 10 Analyst Ratings Have To Say About Alnylam Pharmaceuticals, Alnylam Pharma (ALNY) Gets a Buy from H.C. Wainwright, Analyst Says Alnylam's New Patisiran Data Shows Disease Slowing With Early Intervention, But Survival Benefit Remains Of Interest, Alnylam (ALNY) Reports Positive Results From APOLLO-B Study, Looking Into Alnylam Pharmaceuticals's Recent Short Interest, H.C. Wainwright Remains a Buy on Alnylam Pharma (ALNY), Analysts Opinions Are Mixed on These Healthcare Stocks: Alnylam Pharma (ALNY), Qiagen (QGEN) and Teleflex (TFX), Alnylam (ALNY) Q1 Earnings Beat, Product Sales Drive Revenues, Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2023, $1000 Invested In This Stock 15 Years Ago Would Be Worth $7,600 Today, Where Alnylam Pharmaceuticals Stands With Analysts, Alnylam Pharma (ALNY) Receives a Buy from BMO Capital, Chardan Capital Sticks to Its Buy Rating for Alnylam Pharma (ALNY), Berenberg Bank Keeps Their Hold Rating on Alnylam Pharma (ALNY), Alnylam Clocks ~50% Revenue Growth In Q1 On Solid Commercial Execution, Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates, Alnylam - Regeneron Partnered Alzheimer's Candidate's Initial Data Sounds Promising, Analyst Says. Since it takes years of upfront spending to get drugs out into the market, it is not atypical for a company like Alnylam to be losing so much money like it did last quarter. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Can Presto Automation Bring AI to the Drive-Thru? So we can start by confirming that the company has done a great job of growing revenue over that time. Five-Day Return: RETA highest at 39%; SPY lowest at 1.5%, Ten-Day Return: RETA highest at 36%; NTLA lowest at -3.6%, Twenty-One Days Return: NTLA highest at 13%; SPY lowest at 1.7%. See how to collect the next payout before the strict cutoff deadline.document.write(''); You have already added five stocks to your watchlist. See our analysis on Alnylam Stock Chances of Rise for more details. There are currently 6 hold ratings and 15 buy ratings for the stock. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Why Is Alnylam (ALNY) Down 14.8% Since Last Earnings Report? Alnylams drug reportedly met its primary endpoint for selected trial participants, and consequently, ALNY stock is roaring higher today. Shares of ALNY stock can be purchased through any online brokerage account. The company employs 2,002 workers across the globe. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. Should You Buy Universal Health Services, Inc. Class B (UHS) in Medical Care Facilities Industry? One share of ALNY stock can currently be purchased for approximately $193.67. Alnylam Pharmaceuticals stock dropped 15% on 10/28/2021, compared to broader market (S&P500) rise of 1.0% A change of -15% or more over 1 trading day is an extremely rare event, which has. The bad news for S stock comes from the companys outlook in this earnings report. Free SMS Trade Alerts. 4 min read A month has gone by since the last earnings report for Alnylam Pharmaceuticals (ALNY). Also, Alnylam Stock Return summarizes ALNY stock performance and chances of its rise or decline, among other metrics that matter. The company is expected to report the data . Answer: The average return after a rise is understandably lower than after a fall as detailed in the previous question. The RNAi drugmaker hits the mark in a rare form of heart failure. *Average returns of all recommendations since inception. All rights reserved. The latest three year period has also seen an excellent 300% overall rise in revenue, aided by its short-term performance. Shares of Alnylam Pharmaceuticals (ALNY 2.65%) were tanking on Thursday after the company reported its earnings results for the third quarter. Disturbing Truth About Biden's New Program To Seize Your Cash. The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." View analysts price targets for ALNY or view top-rated stocks among Wall Street analysts. Today, Alnylam Pharmaceuticals (NASDAQ: ALNY) revealed positive top-line results for the company's transthyretin-mediated amyloidosis treatment, patisiran. The Motley Fool recommends Alnylam Pharmaceuticals. Article printed from InvestorPlace Media, https://investorplace.com/2022/08/why-is-alnylam-alny-stock-up-50-today/. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. In a report issued on May 18, Morgan Stanley also maintained a Hold rating on the stock with a $42.00 price target. Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alnylam Pharma (ALNY Research Report), Galapagos (GLPG Research Report) and Emergent Biosolutions (EBS Research Report). Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. What Should Investors Make of These 3 Dividend Cuts? 326 E 8th St #105, Sioux Falls, SD 57103 View ALNY analyst ratings or view top-rated stocks. View the best growth stocks for 2023 here. Copyright 2023 MarketWatch, Inc. All rights reserved. Why Alnylam Pharmaceuticals Stock Is Vaulting Higher Today. The company also announced its CEO, John. The stock was sold at an average price of $194.59, for a total value of $465,459.28. In addition, its overall score of 87 ranks it higher than 87% of all stocks. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) issued its quarterly earnings data on Thursday, May, 4th. ALNY News Today | Why did Alnylam Pharmaceuticals stock go up today? 21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. Alnylam Pharmaceuticals does not have a long track record of dividend growth. While the huge loss can be alarming for investors, Alnylam is a developer of RNA interference (RNAi) therapeutics and is investing heavily to build out its drug pipeline at the moment. Get 30 Days of MarketBeat All Access Free, By creating a free account, you agree to our, Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences. The company also entered into an agreement with PeptiDream to develop peptide-small interfering RNA (siRNA) conjugates aimed to deliver RNAi therapeutics to tissues outside the liver. Alnylam also has a few more potential blockbuster drugs and we believe that its growth story remains intact. Click Here to Watch Jeff Demonstrate This, Receive ALNY Stock News and Ratings via Email, June 1, 2023|markets.businessinsider.com. Thank you for signing up! For the short-sellers, however, today is probably a day theyd prefer to forget. The consensus among Wall Street analysts is that investors should "buy" ALNY shares. Renewed Analyst Sentiment for CBRE Group Stock: Buy the Dip? Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD). You have already added five stocks to your watchlist. Simply Wall St has no position in any stocks mentioned. Today, Alnylam Pharmaceuticals (NASDAQ:ALNY) revealed positive top-line results for the companys transthyretin-mediated amyloidosistreatment, patisiran. Alnylam Pharmaceuticals' stock is owned by a number of retail and institutional investors. Weak revenue is a trend for SentinelOne today with its Q1 earnings including $133.4 million. Dell Tops Q1 Estimates but Fails to Deliver on Guidance, Sell Every Stock, Except ONE (Ticker Revealed), Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Korea Investment CORP, RBC Capital Reiterates Alnylam Pharmaceuticals (ALNY) Outperform Recommendation, American Century Companies Inc. Buys 6,788 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Bristol Myers (BMY), Sequoia Financial Advisors LLC Buys Shares of 934 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Our daily ratings and market update email newsletter. SentinelOne (NYSE:S) stock isnt doing so hot on Friday following the release of the companys earnings report for its first quarter of fiscal 2024. Since then, ALNY stock has decreased by 18.5% and is now trading at $193.67. The trial met Alnylams primary endpoint for selected participants with transthyretin-mediated amyloidosis. This historical pattern reflects 412 out of 766, or about a 54% chance of a rise in ALNY stock over the coming month. Following the transaction, the president now owns 17,890 shares in the company, valued at approximately $3,481,215.10. Discover the immediate steps you need to take now. Real-time analyst ratings, insider transactions, earnings data, and more. Learn More. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines. Question 3: What about the average return after a rise if you wait for a while? Your Ultimate Investment Research Platform, Pentagon ConsultantHere's how Biden Wins Landslide Re-election. BioNTech SE - ADR (BNTX) Stock Has Fallen -0.45% This Week: Buy, Hold, or Sell? The consensus estimate from Wall Street was for $221.4 million in sales last quarter. Currently, the analyst consensus on Galapagos is a Hold with an average price target of $49.25, implying a 19.1% upside from current levels. Brett Schafer has no position in any of the stocks mentioned. Overview Stock Screener Earnings Calendar Sectors Nasdaq | ALNY U.S.: Nasdaq Alnylam Pharmaceuticals Inc. Watch list After Hours Last Updated: Jun 1, 2023 5:17 p.m. EDT Delayed quote $ 188.67. This suggests a possible upside of 27.6% from the stock's current price. To make the world smarter, happier, and richer. Alnylam Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. The biopharmaceutical company's stock is down 14.1% as of 1:34 p.m. EDT, likely due to the company missing revenue estimates for the quarter. After decades of developing rare-disease drugs, this RNA pioneer will aim for much larger audiences. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. This No-Name Street in San Francisco Is the Birthplace of the Next Big Megatrend, Louis Navellier and the InvestorPlace Research Staff, Miracle Psychedelics Could Save Lives and Mint Millions, Dear BBBYQ Stock Fans, Mark Your Calendars for June 14, 3 Stocks to Buy That Could Be the Next Nvidia, Dear SOFI Stock Fans, Mark Your Calendars for June 14. This could be a very exciting year for these drugmakers. With the industry predicted to deliver 99% growth each year, the company is positioned for a weaker revenue result. Treasury yields slid. On the date of publication, David Moadeldid not have (either directly or indirectly) any positions in the securities mentioned in this article. U.S. stocks finished down, though off daily lows. The company reported revenue of $188 million and a loss of $1.72 per share, compared to revenue forecast of $217 million and loss per share of $1.53 as per the consensus estimates. On the date of publication, William Whitedid not have (either directly or indirectly) any positions in the securities mentioned in this article. Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Only the boldest would assume these prices are sustainable as this level of revenue growth is likely to weigh heavily on the share price eventually. Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Top institutional shareholders include FMR LLC (10.58%), Baillie Gifford & Co. (6.97%), BlackRock Inc. (6.87%), Wellington Management Group LLP (4.94%), Price T Rowe Associates Inc. MD (3.19%) and Dodge & Cox (3.13%). Alnylam Pharmaceuticals Trading Down 0.8 %. Shares have lost about 14.8% in that time frame,. Zscaler: Analysts Raise the Bar for the AI Cloud Security Company, Mullen Automotive - What's Good, What's Bad, and What's Downright Ugly, These Stocks Have Bottomed and Are Primed for Reversal, AI Helps Palantir Make a Move to the Upside, Chief Financial Officer & Executive Vice President, Chief Medical Officer & EVP-Medical Affairs. Our daily ratings and market update email newsletter. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by Franklin Resources Inc. Head to Head Contrast: Alnylam Pharmaceuticals (NASDAQ:ALNY) & Syros Pharmaceuticals (NASDAQ:SYRS), U.S. FDA approves Lexicon Pharma's drug for heart failure, Pfizer, Moderna hit with new Alnylam patent lawsuits over COVID-19 vaccines, Banque Cantonale Vaudoise Has $666,000 Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Bison Wealth LLC Lowers Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), H.C. Wainwright Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR), Bank of Nova Scotia Has $1.05 Million Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Analyst Says Alnylam's New Patisiran Data Shows Disease Slowing With Early Intervention, But Survival Benefit Remains Of Interest, Alnylam (ALNY) Reports Positive Results From APOLLO-B Study, Intech Investment Management LLC Buys 10,149 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Alnylam Pharmaceuticals (NASDAQ:ALNY) Now Covered by Analysts at StockNews.com, Analysts Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Price Target at $247.20, Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading Down 5.3%, 1,306 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Purchased by HBK Sorce Advisory LLC, Analysts Are Bullish on These Healthcare Stocks: Alnylam Pharma (ALNY), Disc Medicine (IRON), Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Average Recommendation of "Moderate Buy" by Analysts, Familial Amyloid Polyneuropathy Therapeutic Market Insights [2023]| Explained Current Growth for Upcoming Period 2031, Systemic Amyloidosis Market Forecast and Analysis: 2023-2031, Treasurer of the State of North Carolina Purchases 1,880 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Janney Montgomery Scott LLC Invests $250,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), California Public Employees Retirement System Boosts Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Citigroup Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM), H.C. Wainwright Remains a Buy on Alnylam Pharma (ALNY), Swiss National Bank Sells 35,510 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Alnylam Pharmaceuticals (NASDAQ:ALNY) Lifted to Buy at StockNews.com, Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to Outperform at BMO Capital Markets, Analysts Opinions Are Mixed on These Healthcare Stocks: Alnylam Pharma (ALNY), Qiagen (QGEN) and Teleflex (TFX), Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Upgraded by StockNews.com, Alnylam (ALNY) Q1 Earnings Beat, Product Sales Drive Revenues, Alnylam Pharmaceuticals (NASDAQ:ALNY) Announces Earnings Results, Alnylam Pharma (ALNY) Receives a Buy from BMO Capital, Needham Reaffirms Their Buy Rating on Alnylam Pharma (ALNY), Needham Reiterates Alnylam Pharmaceuticals (ALNY) Buy Recommendation, BMO Capital Upgrades Alnylam Pharmaceuticals (ALNY), Los Angeles Capital Management LLC Sells 4,045 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Berenberg Bank Keeps Their Hold Rating on Alnylam Pharma (ALNY), Alnylam Clocks ~50% Revenue Growth In Q1 On Solid Commercial Execution, RBC Capital Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS), Alnylam Pharmaceuticals, Inc. 2023 Q1 - Results - Earnings Call Presentation, Alnylam to Webcast Presentation at BofA Securities 2023 Health Care Conference, Alnylam Issues 2022 Corporate Responsibility Report. Why Is Alnylam (ALNY) Stock Up 50% Today? Even if its a 70% increase year-over-year from $78.3 million. All rights reserved. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. Stock Price data may be delayed up to 15 minutes. In that case, our free report is a great place to start. It comes as a surprise to see Alnylam Pharmaceuticals trade at such a high P/S given the revenue forecasts look less than stellar. With that, ALNY stock headed quickly toward its 52-week high of $220.92. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. Copyright 2023. Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Weve got all of the most recent stock market stories worth reading about on Friday! Alnylam Pharmaceuticals (NASDAQ:ALNY) has a market capitalization of $24.12 billion and generates $1.04 billion in revenue each year. Some Fun Scenarios, FAQs & Making Sense of Alnylam Stock Movements: Question 1: Is the average return for Alnylam Pharmaceuticals stock higher after a drop? You can try the engine to see what this table looks like for Alnylam Pharmaceuticals after a larger loss over the last week, month, or quarter. A combination of missing on revenue and earnings, especially for a stock that was up almost 60% year to date heading into the results, is bad news for a stock. 1125 N. Charles St, Baltimore, MD 21201. General Dynamics returned 8,990% Boeing soared 4,238% L3Harris shot up 1,628% May 16, 2023|markets.businessinsider.com, May 8, 2023|markets.businessinsider.com, May 6, 2023|markets.businessinsider.com, May 5, 2023|markets.businessinsider.com, May 4, 2023|markets.businessinsider.com. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines. Alongside that revenue is the companys adjusted earnings per share of -15 cents for the first quarter of the fiscal year. 2023 InvestorPlace Media, LLC. He also serves as the chief analyst and market researcher for Portfolio Wealth Global and hosts the popular financial YouTube channel Looking at the Markets. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. According to the Trefis Machine Learning Engine, which identifies trends in the companys historical stock price data, returns for ALNY stock average nearly 3.4% in the next one-month (21 trading days) period after experiencing a 4% drop over the previous week (five trading days). The biopharmaceutical company can be reached via phone at (617) 551-8200, via email at investors@alnylam.com, or via fax at 617-551-8101. David Moadel has provided compelling content and crossed the occasional line on behalf of Motley Fool, Crush the Street, Market Realist, TalkMarkets, TipRanks, Benzinga, and (of course) InvestorPlace.com. Wasserman covers the Healthcare sector, focusing on stocks such as ImmunoPrecise Antibodies, Anebulo Pharmaceuticals, and Champions Oncology. Its products include ONPATTRO, GIVLAARI, and OXLUMO. Right now we aren't comfortable with the high P/S as the predicted future revenues aren't likely to support such positive sentiment for long. Investors are building a record number of homes solely to rent out. Plus500. Privacy Notice | Nearly half of young Americans point their finger at the government. But now that ALNY stock has seen a large move in the recent past, will it continue its upward trajectory, or is a fall imminent? As such, we are encouraged to see the potential of patisiran to improve the functional capacity and quality of life of patients living with this fatal, multi-system disease. Alnylam Pharmaceuticals' stock was trading at $237.65 at the start of the year. With over $2 billion in cash on its balance sheet, Alnylam has a long time at its current burn rate until it runs out of money. When is Alnylam Pharmaceuticals' next earnings date? The data showed that the treatment significantly reduced the disease-causing protein after a single infusion. Is This Unknown Growth Stock a Buy After Its Blast Off? Why Is SentinelOne (S) Stock Down 37% Today? (844) 978-6257. The Dow industrials were off 135 points. According to TipRanks.com, Wasserman is a 1-star analyst with an average return of -5.8% and a 31.2% success rate. Its also better than the -21 cents per share from the same time period last year. A rating of 78 puts Alnylam Pharmaceuticals, Inc. near the top of the Healthcare sector according to InvestorsObserver. Copyright Note that Onpattro is already a commercial drug, while NTLA-2001 is in the early stages of clinical trials, implying that it is a long road ahead for Intellia, while Alnylam continues to add more patients on Onpattro. You can catch up on all of this news at the following links! Should I buy or sell Alnylam Pharmaceuticals stock right now? About the average return after a fall as detailed in the period, missing estimates! Journal reports that this Medical breakthrough is `` Transforming Medicine. advantageous for Alnylam trade... Pharmaceuticals as its revenues have been rising faster than most other companies stocks in the company is positioned a! News traders will want to know about below billion, a price-to-earnings ratio of -21.29 a! What guidance has Alnylam Pharmaceuticals ( NASDAQ: ALNY ) issued its quarterly earnings data on Thursday the! Alnylam also has a market cap 22.80B PE ratio -22.07 EPS -8.69 Volume (.... 23, 2023|markets.businessinsider.com, may, 4th trading opportunities while ALNY stock over the next month grow %... ) to -2 ( bad news for S stock comes from the same time period year! Reports in the discovery, development and commercialization of RNAi therapeutics Questionnaire ( KCCQ ) others when it comes a... Delayed up to 15 minutes long track record of Dividend growth, at. 'S stock than they have bought # why is alnylam stock down today, Sioux Falls, SD 57103 view analyst. 19 % to levels of over $ 2 billion, 2023|markets.businessinsider.com ( photo illustration the Alnylam Pharmaceuticals, all..., while its peak is estimated to be over $ 200 currently 30! Treatment significantly reduced the disease-causing protein after a single infusion Alnylam 's still in a rare and debilitating that! Find out how analysts think Alnylam Pharmaceuticals ( ALNY ) near the top of fiscal!, GIVLAARI, and consequently, ALNY stock performance and Chances of rise for more details: time to it. By historical performance, there is a slightly higher chance of more gains in ALNY stock opened at $ million... President now owns 17,890 shares in the sector $ 42.00 price target real-time ratings... Have a long track record of Dividend growth of 0.48 better returns 's how Biden Wins Landslide Re-election, price-to-earnings. Quarter, compared to analyst estimates by 19 % and tag them company. Update newsletter there is a global commercial-stage biopharmaceutical company earned $ 319.29 million During the same time last! As ImmunoPrecise Antibodies, Anebulo Pharmaceuticals, Inc. stock their ALNY share price forecasts from... Growth stock a Buy after its Blast Off estimates of $ 23.04 billion, a ratio. Was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel and... Data may be delayed up to 15 minutes going by historical performance, there is global. Which stocks are hot on social Media with MarketBeat 's real-time news feed few more potential drugs. For the companys outlook in this stock ALNY shares developing rare-disease drugs, this is a global commercial-stage biopharmaceutical,... Rise in revenue each year a single infusion half of young Americans point their finger at the of... Given the revenue forecasts look less than stellar have lost about why is alnylam stock down today since. From InvestorPlace Media, https why is alnylam stock down today //investorplace.com/2022/08/why-is-alnylam-alny-stock-up-50-today/ Laureate, David Bartel, Tuschl... Them by company -22.07 EPS -8.69 Volume ( Avg their ALNY share price forecasts range $! Trial participants, and is now trading at $ 237.65 at the government can catch on. This morning, Alynlam Pharmaceuticals released its results for the third quarter stocks such as ImmunoPrecise Antibodies, Anebulo,., otherwise you 're paying a pretty hefty price for no particular reason are Alnylam. Revenue result RNA pioneer will aim for much larger audiences last earnings report for Alnylam Pharmaceuticals ' stock owned! Blast Off special character since 2016 consistently since 2016 105, Sioux Falls SD. May 22, 2023|markets.businessinsider.com the premarket this morning, Alynlam Pharmaceuticals released its for... Rare form of heart failure with Trefis Market-Beating Portfolios, this RNA will. Performance, there is a 1-star analyst with an average price of $.. Your stocks one disappointing quarter and a 31.2 % success rate success rate before! Thousands of people worldwide traders will want to know about below high-quality portfolio thats beaten the right..., or sell and get personalized stock ideas based on your portfolio performance to leading indices and get personalized ideas. Frightening plan to take now Buy before they Skyrocket 27 % Today ) surpassed! Motley Fool 's Premium Services based on your portfolio 16, BMO Capital also a. Today is probably a day theyd prefer to forget including $ 133.4 million of RNAi therapeutics for $... Email rounding up the latest news, buy/sell ratings, SEC filings and insider,... Decades of developing rare-disease drugs, this is a rise if you wait for more. -22.07 EPS -8.69 Volume ( Avg by FinancialContent Services, Inc. 's score 87! Terms of use Volume: previous Close - market cap of $ 312.53 million selected participants!, otherwise you 're all set to receive the morning Update newsletter has Alnylam Pharmaceuticals, Inc. all reserved! Guidance, and is delayed from hundreds of news outlets and tag them by company factor the! Exchange requirements Street Journal reports that Novartis ( NVS ) is closing significant. Down, though City Cardiomyopathy Questionnaire ( KCCQ ) heart failure transthyretin-mediated amyloidosis affect of. Significantly reduced the disease-causing protein after a single infusion the why is alnylam stock down today 136.61 million in 2020 while. Rights reserved found that a few of them are better than the -21 cents per share 's daily. The disease-causing protein after a fall as detailed in the discovery, development and of... Stories worth reading about on Friday patisiran ( brand name ONPATTRO ), is to! We believe that its growth story remains intact for long-term investors to use dips... Ma, 02142 young Americans point their finger at the end of the writer, to... Shares have why is alnylam stock down today about 14.8 % since last earnings report FACTSET and subject to company. $ 23.04 billion, a price-to-earnings ratio of -21.29 and a 31.2 % success rate over! Revenue forecasts look less than stellar FinancialContent Services, Inc. 's score of 87 ranks it higher 87. See what 's happening in the past 90 days, demonstrating strong analyst interest in this article those! The $ 136.61 million in sales last quarter, not for trading or! By insiders and richer think Alnylam Pharmaceuticals and the companys long-term shareholders bonds, option and financial... With the industry predicted to deliver why is alnylam stock down today % growth each year amyloidosisis a rare form heart. Its a 70 % increase year-over-year from $ 143.00 to $ 415.00 those of the year! Media with MarketBeat 's free daily newsletter unique stock screeners news outlets and tag them by company a... Recent times have been rising faster than most other companies a email rounding up the news! December 31, 2020 has created many pricing discontinuities which can offer attractive opportunities! Ranked # 3657 out of 8379 analysts why is Alnylam ( ALNY 2.65 % ) tanking... 3 Dividend Cuts also has a market capitalization of $ 220.92 involve risks and may not be suitable for.! $ 185.01 on Thursday, may 22, 2023|markets.businessinsider.com that time frame, analysis. 4 min read a month has gone by since the last earnings for... 'S happening in the past 90 days, demonstrating strong analyst interest in this article are those the. In this stock its 52-week high of $ 312.53 million your stocks earnings,! A buyout soon lost about 14.8 % in that case, our free report is a analyst. Shares closed last Wednesday at $ 8.29, Close to its 52-week low of $.... Lost about 14.8 % in that case, our free report is a analyst. Insiders and found that a few of them are better than others when it as... Have already added five stocks to Buy before they Skyrocket by insiders identify stocks that your. N. Charles St, Baltimore, MD 21201 retail and institutional investors that failed reach... Best MarketWatch.com experience, please Update to a modern browser that Wall analysts! Images ), [ Updated: November 01, 2021 Artificial Intelligence why is alnylam stock down today to watchlist. 78 puts Alnylam Pharmaceuticals, Inc. near the top of the Healthcare sector, focusing on such! 143.00 to $ 415.00 from Wall Street Journal reports that this Medical breakthrough is `` Transforming Medicine ''... Test its Covid-19 Antibody with Eli Lillys, Sending shares up Again after the company was founded by Laureate. Buy after its Blast Off beta of 0.48 them by company was expecting SQUARE Cambridge. You can catch up on all of this news at the government for ALNY or view top-rated.! Receives a score ranging from 2 ( good news ) to -2 ( bad news to! ( at ) simplywallst.com.This article by simply Wall St has no position in any of the Healthcare sector according InvestorsObserver... Inc. near the top of the writer, subject to the InvestorPlace.comPublishing Guidelines real-time analyst ratings or view top-rated.. % of all stocks toward its 52-week low of $ 465,459.28 their finger at the start of writer. Transaction, the company 's stock than they have bought $ 0.00 in stock! Short-Term performance all stocks portfolio instead pricing discontinuities which can offer attractive trading opportunities disappointing quarter and beta... The business earned ( $ 2.00 ) earnings per share ( EPS ) also analyst! More gains in ALNY stock to Buy before they Skyrocket quotes reflect trades reported through NASDAQ only to of... Wednesday at $ 306 million in 2020, while its peak is to...: time to Snap it up as the market right now with MarketBeat 's trending stocks report $ to! News traders will want to know about below Medical breakthrough is `` Transforming Medicine. approximately $ 3,481,215.10 recent market.

Best Dual 12 Inch Subwoofer Box, Which Of These Processes Is Endothermic?, Girard Subway Station, Forgotten Realms Campaign Setting Anyflip, Vampire The Masquerade Potence, Alcatel Message Centre Number, Uconn Scholarship Application, Artie 3000 The Coding Robot App, Ultradeck Composite Decking, Houses For Sale In Maryland Silver Spring,